Table 1 Baseline characteristics of patients according to neoadjuvant chemotherapy regimen (n = 450)
|  | Non-carboplatin (N = 247) | Carboplatin (N = 120) | Pembrolizumab (N = 83) | Total (N = 450) | P |
|---|---|---|---|---|---|
Age, n (%) | Â | Â | Â | Â | 0.630 |
 ≤ 50 | 143 (57.9) | 75 (62.5) | 47 (56.6) | 265 (58.9) |  |
 > 50 | 104 (42.1) | 45 (37.5) | 36 (43.4) | 185 (41.4) |  |
Germline BRCA1/2 mutation* | Â | Â | Â | Â | 0.090 |
 No | 86 (81.9) | 64 (70.3) | 56 (82.4) | 206 (78.0) |  |
 Yes | 19 (18.1) | 27 (29.7) | 12 (17.6) | 58 (22.0) |  |
Clinical tumor stage | Â | Â | Â | Â | 0.156 |
 1 | 14 (5.7) | 7 (5.8) | 6 (7.2) | 27 (6.0) |  |
 2 | 163 (66.0) | 91 (75.8) | 62 (74.7) | 316 (70.2) |  |
 3 | 51 (20.6) | 18 (15.0) | 14 (16.9) | 83 (18.4) |  |
 4 | 19 (7.7) | 4 (3.3) | 1 (1.2) | 24 (5.3) |  |
Clinical nodal stage | Â | Â | Â | Â | 0.280 |
 0 | 47 (19.0) | 25 (20.8) | 11 (13.3) | 83 (18.4) |  |
 1 | 100 (40.5) | 51 (42.5) | 43 (51.8) | 194 (43.1) |  |
 2 | 87 (35.2) | 36 (30.0) | 21 (25.3) | 144 (32.0) |  |
 3 | 13 (5.3) | 8 (6.7) | 8 (9.6) | 29 (6.4) |  |
Clinical Stage, n (%) | Â | Â | Â | Â | 0.133 |
 I, IIA | 49 (19.8) | 24 (20.0) | 13 (15.7) | 86 (19.1) |  |
 IIB | 75 (30.4) | 41 (34.2) | 37 (44.6) | 153 (34.0) |  |
 IIIA | 93 (37.7) | 43 (35.8) | 24 (28.9) | 160 (35.6) |  |
 IIIB | 17 (6.9) | 4 (3.3) | 1 (1.2) | 22 (4.9) |  |
 IIIC | 13 (5.3) | 8 (6.7) | 8 (9.6) | 29 (6.4) |  |
Histologic grade*, n (%) |  |  |  |  | 0.369†|
 1 | 4 (2.2) | 0 | 1 (1.3) | 5 (1.3) |  |
 2 | 85 (47.0) | 53 (46.5) | 44 (55.0) | 182 (48.5) |  |
 3 | 92 (50.8) | 61 (53.5) | 35 (43.8) | 188 (48.5) |  |
sTILs, median (range) | 20 (10–60) | 20 (3–40) | 10 (3–25) | 20 (3–40) | < 0.001 |
sTILs*, % | Â | Â | Â | Â | 0.009 |
 < 50 | 120 (68.2) | 90 (78.9) | 67 (84.8) | 277 (75.1) |  |
 ≥ 50 | 56 (31.8) | 24 (21.1) | 12 (15.2) | 92 (24.9) |  |
Surgery type | Â | Â | Â | Â | 0.512 |
 Lumpectomy | 137 (55.5) | 74 (61.7) | 49 (59.0) | 260 (57.8) |  |
 Mastectomy | 110 (44.5) | 46 (38.3) | 34 (41.0) | 190 (42.2) |  |